143
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Vitamin derivatives as potential drugs for Influenza Hemagglutinin

, , , , &
Pages 11781-11795 | Received 30 Oct 2021, Accepted 23 Dec 2022, Published online: 11 Jan 2023
 

Abstract

The objective of the study was to identify potential inhibitors of Influenza surface Hemagglutinin (HA), which plays key role in the entry and replication of Influenza virus into the host cell. As ligands, seven vitamins and their derivatives were selected after initial screening based on their metabolizable capacity with no reported side effects, for in silico studies. Docking, and Post docking analysis (X Score and Ligplot+) were performed against nine Influenza HA targets for the vitamins and its derivatives. ‘Vitamin Derivatives’ with top docking score were further analysed by MD Simulations and free energy was calculated using MMGBSA module. FMNNa and FMNCa displayed high binding free energy with Influenza HA, thereby exhibiting potential as HA inhibitors.

Communicated by Ramaswamy H. Sarma

Acknowledgments

The authors acknowledge the facilities and Faculty Research Grant Scheme (FRGS) support provided by Guru Gobind Singh Indraprastha University, Delhi, India. Also, we acknowledge Dr. Ranjana Arya (School of Biotechnology, Jawaharlal Nehru University, New Delhi) and Dr. Manish (School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi).

Availability of data and material

Yes.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethical standard statement

All the research studies performed are virtual (Computational). No experimental work has been carried out on animals and humans.

Funding

The author(s) reported there is no extramural funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.